INZY Company Profile and Key Details

Q: Who are the executives of INZY?

Dr. David Thompson M.A., M.S., Ph.D.Senior Vice President, Chief Scientific Officer & Chief Devel. OfficerDr. Soojin Kim Ph.D.Senior Vice President & Chief Technical Operations OfficerDr. Yves Sabbagh Ph.D.Chairman of Scientific Advisory Board & Senior Vice PresidentMr. Henric Bjorn BjarkeConsultantDr. Matthew Winton Ph.D.Senior Vice President & Chief Operating OfficerMr. Sanjay S. Subramanian M.B.A., M.S.Senior Vice President, Chief Financial Officer & Principal Accounting OfficerMs. Gayle GirondaSenior Vice President & Chief People OfficerMr. Stefan RileyDirector of Investor RelationsMr. Axel Bolte M.B.A., M.Sc.Co-Founder, Pres, Chief Executive Officer & DirectorDr. Demetrios Braddock M.D., Ph.D.Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board ObserverDr. Douglas A. Treco Ph.D.Chief Executive Officer & ChairmanDr. Kurt C. Gunter FASCP, M.D., Ph.D.Chief Medical Officer

NASDAQ : INZY

Inozyme Pharma

$4.00

0.01+0.25%

At Close 4:00 PM

Not Actively Trading

69.54

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Inozyme Pharma, Inc. (INZY) stock surged +0.25%, trading at $4.00 on NASDAQ, up from the previous close of $4.00. The stock opened at $4.00, fluctuating between $4.00 and $4.00 in the recent session.

Stock Snapshot

Prev. Close

258.25M

Market Cap

Day Low

-2.380952380952381

P/E Ratio

-1.68

EPS (TTM)

-1.15

Cash Flow per Share

Open

64.56M

Number of Shares

Day High

67.18%

Free Float in %

2.27

Book Value

1.46M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 30, 2025	4.00	4.00	3.99	4.00	1.46M
Jun 27, 2025	4.00	4.00	3.99	3.99	4.91M
Jun 26, 2025	4.00	4.00	3.99	4.00	386.44K
Jun 25, 2025	3.99	4.00	3.99	3.99	813.36K
Jun 24, 2025	3.99	4.00	3.99	3.99	1.16M
Jun 23, 2025	3.99	4.00	3.98	3.99	1.02M
Jun 20, 2025	3.99	3.99	3.98	3.99	771.61K
Jun 18, 2025	3.98	3.99	3.98	3.99	696.4K
Jun 17, 2025	3.98	3.99	3.98	3.99	592.99K
Jun 16, 2025	3.99	3.99	3.97	3.97	701.12K
Jun 13, 2025	3.98	3.99	3.97	3.99	431.5K
Jun 12, 2025	3.98	3.98	3.97	3.98	302.73K
Jun 11, 2025	3.97	3.98	3.97	3.97	388.9K
Jun 10, 2025	3.98	3.99	3.97	3.98	920.38K
Jun 09, 2025	3.99	3.99	3.97	3.98	1.03M
Jun 05, 2025	3.98	3.99	3.98	3.99	1.18M
Jun 04, 2025	3.97	3.99	3.97	3.98	1.48M
Jun 03, 2025	3.97	3.99	3.97	3.98	1.02M
Jun 02, 2025	3.96	3.98	3.96	3.98	1.8M
May 30, 2025	3.95	3.97	3.95	3.97	1.09M

Contact Details

Boston, MA 02210

United States

https://www.inozyme.com 857 330 4340

About Company

Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure. The company's flagship therapeutic candidate, INZ-701, is an engineered, soluble protein under development to combat specific genetic conditions, namely ENPP1 and ABCC6 deficiencies, as well as for the management of calciphylaxis. Inozyme maintains a licensing arrangement with Yale University concerning particular therapeutic and preventative agents. Established in 2015, the firm's main offices are situated in Boston, Massachusetts.

Stock Peers

ARGX

-4.64-0.50%

argenx SE$915.30 REGN

-13.35-1.97%

Regeneron Pharmaceuticals, Inc.$662.88 MDGL

20.04+3.67%

Madrigal Pharmaceuticals, Inc.$565.40 UTHR

-9.36-1.66%

United Therapeutics Corporation$554.34 VRTX

-23.82-4.56%

Vertex Pharmaceuticals Incorporated$498.43 KRYS

6.8+1.84%

Krystal Biotech, Inc.$375.40 PRAX

9.04+2.79%

Praxis Precision Medicines, Inc.$332.99 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.91+0.59%

Alnylam Pharmaceuticals, Inc.$323.50 LGND

-4.55-1.42%

Ligand Pharmaceuticals Incorporated$314.88

Company Overview

The stock is currently mid-range between its 52-week high and low $0.72 and $6.24. With a market capitalization of about $258.25 million, Inozyme Pharma, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.29). Key stats such as the average daily volume over the past year has been around 2.26 million shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, Inozyme Pharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Douglas A. Treco, the company employs approximately 67 people and listed since July 24, 2020. Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 0.37%, SMA50 40.19%, SMA200 43.56%). The stock’s 14-day RSI is 82.7 (overbought), while the ATR of 0.05 points to moderate volatility. The stock remains hovering near 52-week lows, trading -35.9% below its high and over 454.79% above its low.

Valuation Metrics

Inozyme Pharma, Inc. trades at a P/E ratio of -2.47, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.34 trading at moderately above to book value. The P/FCF stands at -2.81, also above market averages.

Dividend & Fair Value

Inozyme Pharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.41. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Inozyme Pharma, Inc. generated EPS of -$1.68 over the past year. Five-year average earnings growth is -13.98%. Wall Street analysts project EPS growth of 17.79% annually over the next five years. The latest quarter delivered EPS of -$0.44. The next quarter is forecast at -$0.38. Next year's EPS is expected at $0.21. Inozyme Pharma, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 05, 2025, missed forecasts by 22.22%. The prior quarter beat by 2.33%. Over the last six quarters, Apple has recorded several small beats. These include 8.57% in May 07, 2024.

Shareholding & Insider Activity

Inozyme Pharma, Inc. has 64.56 million shares outstanding. The public float is 30.01 million shares, elevated short interest at 6.16% of float. This equals 3.68 million shares. The short ratio is 0.75 days. Institutional investors hold 95.49% of the float. Insiders own 1.26%. ENRIGHT PATRICK G holds 4.17 million shares, Longitude Capital Partners III, LLC has 4.17 million shares and Pivotal bioVenture Partners Fund I U.G.P., Ltd has 2.66 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Inozyme Pharma has not generated any revenue. Returns are negative, with ROA at -35.43% and ROE at -50.66%.
On valuation metrics, Inozyme Pharma trades at a P/E of -2.47, P/S of 0.00 and P/B of 4.34. The current ratio is 3.56 and quick ratio is 3.56. Debt-to-equity is 0.81, supported by a cash flow-to-debt ratio of -1.96.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Inozyme Pharma posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $1.29M (margin 0.00%). Operating income was - $75.65M (margin 0.0%). Net income was- $71.17M (EPS - $1.37).
The company ended the quarter with $188.59M in cash and short-term investments, a total debt of $46.59M, and net debt of $12.00M. Total assets were $200.85M, with equity of $140.48M. Financials further reflected weakness, with operating cash flow of - $70.68M, free cash flow of - $70.97M, and capital expenditures of - $298.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Inozyme Pharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.5%, with price expected at $4.62 by July 14, 2025, within a range of $3.57 to $5.57 3-Month Outlook: Projected rise of 444.0%, reaching $21.76 by September 26, 2025, with a range of $21.12 to $22.93. 1-Year Outlook: Projected gain of 260.75%, with price at $14.43 by June 30, 2026, within a range of $0.00 to $32.34.

Key Takeaways

Inozyme Pharma, Inc. (NASDAQ:INZY) shares are up 44.4% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Inozyme Pharma, Inc. trading at a premium to the broader market with a P/E of -2.47. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $17.65, suggesting 341.25% upside. Our AI forecast model points to short-term strength (15.5% over two weeks), a medium-term rise (444.0% over three months), and a longer-term gain (260.75% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Inozyme Pharma, Inc. (INZY) stock price?

Inozyme Pharma, Inc. (NASDAQ: INZY) stock price is $4.00 in the last trading session. During the trading session, INZY stock reached the peak price of $4.00 while $4.00 was the lowest point it dropped to. The percentage change in INZY stock occurred in the recent session was 0.25% while the dollar amount for the price change in INZY stock was $0.01.

INZY's industry and sector of operation?

The NASDAQ listed INZY is part of Biotechnology industry that operates in the broader Healthcare sector. Inozyme Pharma, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of INZY?

Dr. David Thompson M.A., M.S., Ph.D.
Senior Vice President, Chief Scientific Officer & Chief Devel. Officer
Dr. Soojin Kim Ph.D.
Senior Vice President & Chief Technical Operations Officer
Dr. Yves Sabbagh Ph.D.
Chairman of Scientific Advisory Board & Senior Vice President
Mr. Henric Bjorn Bjarke
Consultant
Dr. Matthew Winton Ph.D.
Senior Vice President & Chief Operating Officer
Mr. Sanjay S. Subramanian M.B.A., M.S.
Senior Vice President, Chief Financial Officer & Principal Accounting Officer
Ms. Gayle Gironda
Senior Vice President & Chief People Officer
Mr. Stefan Riley
Director of Investor Relations
Mr. Axel Bolte M.B.A., M.Sc.
Co-Founder, Pres, Chief Executive Officer & Director
Dr. Demetrios Braddock M.D., Ph.D.
Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer
Dr. Douglas A. Treco Ph.D.
Chief Executive Officer & Chairman
Dr. Kurt C. Gunter FASCP, M.D., Ph.D.
Chief Medical Officer

How INZY did perform over past 52-week?

INZY's closing price is 454.79% higher than its 52-week low of $0.72 where as its distance from 52-week high of $6.24 is -35.9%.

How many employees does INZY have?

Number of INZY employees currently stands at 67.

Link for INZY official website?

Official Website of INZY is: https://www.inozyme.com

How do I contact INZY?

INZY could be contacted at phone 857 330 4340 and can also be accessed through its website. INZY operates from 321 Summer Street, Boston, MA 02210, United States.

How many shares of INZY are traded daily?

INZY stock volume for the day was 1.46M shares. The average number of INZY shares traded daily for last 3 months was 2.26M.

What is the market cap of INZY currently?

The market value of INZY currently stands at $258.25M with its latest stock price at $4.00 and 64.56M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	67
Beta	2.29
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

INZY Company Profile and Key Details

Inozyme Pharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Price Forecast & Outlook

Key Takeaways

Valuation Metrics